Recombinant Human MICL/CLEC12A Fc Chimera Protein, CF

When Recombinant Human Integrin alpha X beta 2 Protein (5755-AX) immobilized at 5.00 μg/mL, 100 μL/well, the concentration of Recombinant Human MICL/CLEC12A Fc Chimera (Catalog# 10835-ML) that produces 50% of the optimal binding response is approximately 1.20-12.0 μg/mL.

2 μg/lane of Recombinant Human MICL/CLEC12A Fc Chimera (Catalog # 10835-ML) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 70-85 kDa and 140-170 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human MICL/CLEC12A Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human Integrin alpha X beta 2 Protein (Catalog # 5755-AX) is immobilized at 5.00 μg/mL, 100 μL/well, the concentration of Recombinant Human MICL/CLEC12A Fc Chimera (Catalog# 10835-ML) that produces 50% of the optimal binding response is approximately 1.20-12.0 μg/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human MICL/CLEC12A protein
  

  MD	Human IgG1 (Pro100-Lys330)	IEGR	Human MICL/CLEC12A (Thr67-Ala265) Accession # AAI26292.1
  N-terminus			C-terminus

• Accession #: AAI26292.1
• N-terminal Sequence: Met
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 50 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 70-85 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human MICL/CLEC12A Fc Chimera Protein, CF

• CD371
• CLEC12A
• CLL1
• CLL-1
• C-type lectin domain family 12, member A
• DCAL-2
• MICL

Background

C-type lectin domain family 12 member A (CLEC12A), also known as C-type lectin-like molecule 1 (CLL1), dendritic cell-associated lectin 2 (DCAL-2), myeloid inhibitory C-type lectin-like receptor (MICL), killer cell lectin like receptor-1 (KLRL1) and CD371, is a member of the C-type lectin receptor superfamily. Of the 17 groups in the superfamily, CLEC12A belongs to group V, which lacks the domain for calcium binding typically found in classical carbohydrate-binding CLECs (1). Mature CLEC12A consists of an extracellular domain (ECD) with a single C-type lectin-like domain, a type II transmembrane domain and a cytoplasmic tail containing an immunoreceptor tyrosine-based inhibition motif (ITIM) (3). Within the ECD, human CLEC12A shares 50% and 47% amino acid sequence identity with mouse and rat CLEC12A, respectively. Human CLEC12A differs from mouse CLEC12A in that it is heavily glycosylated and is found as a monomer rather than a dimer (2). CLEC12A is predominantly expressed in innate immune cells and plays a role in immunotherapy (1-6). CLEC12A preferentially associates with the protein tyrosine phosphatases SHP-1 and SHP-2 but not SHIP. Mechanistic studies with chimeric proteins have indicated that, similar to other ITIM-containing receptors, the cytoplasmic tail of CLEC12A can inhibit cellular activation upon ligand binding stimulation. The physiological functions of CLEC12A are poorly understood and the human ligand for CLEC12A is unknown. (7) Most CTL receptors require Ca2+ ions for binding (8). C-type lectins are the most diverse and prevalent lectin family in immunity. Particular interest has recently been attracted by the C-type lectin-like receptors on NK cells, which appear to regulate the activation/inhibitory balance of these cells, controlling cytotoxicity and cytokine production (9). CLEC12A receptor has emerged as a leukemia-associated and cancer stem cell marker in myeloid malignancies (10). CLEC12A is a myeloid lineage antigen that is highly expressed by AML cells and LSCs, but not expressed by normal hematopoietic stem cells (HSCs). The CLEC12A TriKE induced robust NK-cell specific proliferation, enhanced NK-cell activation, and killing of both AML cell lines and primary patient-derived AML blasts in vitro while sparing healthy HSCs. Additionally, the CLEC12A TriKE was able to reduce tumor burden in preclinical mouse models. These findings highlight the clinical potential of the CLEC12A TriKE for the effective treatment of AML (11).

1. Lahoud, M. et al. (2009) J. Immunol. 182:7587.
2. Pyz, E. et al. (2008) Eur. J. Immunol. 38:1157.
3. Morsink, L. et al. (2019) Blood Reviews 34:26.
4. Raulf, M. et al. (2019) Cell Reports 28:30.
5. Bill, M. et al. (2019) Br. J. Haematol. 184:769.
6. Matsuo, H. et al. (2020) Br. J. Haematol. 192:e7.
7. Marshall, A.S. et al. (2004) J. Biol. Chem. 279:14792.
8. Lindenwald D.L. et al. (2020) Int. J. Mol. Sci. 21:5122.
9. Marshall, A.S. et al. (2006) Eur. J. Immunol. 36:2159.
10. Maria, B. et al. (2018) J. Cell. Mol. Med. 22:2311.
11. Arvindam, U.S. et al. (2021) Leukemia 35:1586.

Bioinformatics

• Uniprot:
  • AAI26292.1()